Key Takeaways
- • Chemistry, a venture capital firm, is raising $500 million for its second fund, signaling continued institutional confidence in the firm's investment strategy and track record.
- • The fund raise represents a significant capital deployment vehicle for emerging and growth-stage investments, positioning Chemistry as an active player in the venture capital landscape as of mid-2026.
- • The second fund indicates successful exit performance or portfolio outcomes from Chemistry's initial fund, enabling the firm to secure increased capital commitments from limited partners.
- • This capital raise occurs within a competitive venture market where established firms continue to deploy substantial dry powder despite broader economic considerations.
Summary
Chemistry, a venture capital firm, is raising $500 million for its second fund, according to Wall Street Journal reporting. The fundraise underscores sustained investor appetite for established venture platforms with demonstrated investment capabilities and portfolio management track records.
The $500 million second fund represents a material capital commitment that Chemistry will deploy across its target investment thesis. For limited partners and institutional investors, second-fund fundraises typically signal that a firm has successfully navigated its initial fund cycle, achieved meaningful portfolio outcomes, and earned sufficient confidence to secure expanded capital commitments. The successful close of this fundraise positions Chemistry to scale its investment activities and potentially expand its deal flow capacity.
The venture capital environment in 2026 continues to support substantial fund formations among established managers, despite periodic market volatility. Chemistry's ability to close a $500 million fund reflects the firm's established brand positioning and the willingness of institutional capital—including endowments, family offices, and pension funds—to commit capital to venture vehicles managed by proven teams.
The specific investment focus, geographic strategy, and portfolio construction methodology for Chemistry's second fund have not been detailed in available reporting, leaving open questions about sector concentration, stage focus, and the firm's strategic evolution relative to its initial fund. Investors will likely seek clarity on these parameters as the firm moves into active deployment mode.
The $500 million second fund represents a material capital commitment that Chemistry will deploy across its target investment thesis. For limited partners and institutional investors, second-fund fundraises typically signal that a firm has successfully navigated its initial fund cycle, achieved meaningful portfolio outcomes, and earned sufficient confidence to secure expanded capital commitments. The successful close of this fundraise positions Chemistry to scale its investment activities and potentially expand its deal flow capacity.
The venture capital environment in 2026 continues to support substantial fund formations among established managers, despite periodic market volatility. Chemistry's ability to close a $500 million fund reflects the firm's established brand positioning and the willingness of institutional capital—including endowments, family offices, and pension funds—to commit capital to venture vehicles managed by proven teams.
The specific investment focus, geographic strategy, and portfolio construction methodology for Chemistry's second fund have not been detailed in available reporting, leaving open questions about sector concentration, stage focus, and the firm's strategic evolution relative to its initial fund. Investors will likely seek clarity on these parameters as the firm moves into active deployment mode.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.